Bio-Techne Corp
NASDAQ:TECH
Gross Margin
Bio-Techne Corp
Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.
Gross Margin Across Competitors
| Country | Company | Market Cap |
Gross Margin |
||
|---|---|---|---|---|---|
| US |
|
Bio-Techne Corp
NASDAQ:TECH
|
9.2B USD |
66%
|
|
| US |
P
|
PerkinElmer Inc
LSE:0KHE
|
1.1T USD |
56%
|
|
| US |
|
Thermo Fisher Scientific Inc
NYSE:TMO
|
180.6B USD |
41%
|
|
| US |
|
Danaher Corp
NYSE:DHR
|
147.1B USD |
60%
|
|
| KR |
|
Samsung Biologics Co Ltd
KRX:207940
|
71.2T KRW |
53%
|
|
| CH |
|
Lonza Group AG
SIX:LONN
|
39.6B CHF |
37%
|
|
| US |
|
IQVIA Holdings Inc
NYSE:IQV
|
34.7B USD |
35%
|
|
| US |
|
Agilent Technologies Inc
NYSE:A
|
34.1B USD |
54%
|
|
| CN |
|
WuXi AppTec Co Ltd
SSE:603259
|
256.7B CNY |
42%
|
|
| US |
|
Mettler-Toledo International Inc
NYSE:MTD
|
26.3B USD |
60%
|
|
| IN |
|
Divi's Laboratories Ltd
NSE:DIVISLAB
|
1.8T INR |
60%
|
Bio-Techne Corp
Glance View
Bio-Techne Corp. began its journey with a clear focus: to bridge the gap between biological research and practical applications, a mission that it continues to pursue with zeal. At its core, Bio-Techne operates as a pioneer in the production and distribution of biotechnology products, catering to the needs of the scientific community across the globe. The company specializes in providing essential tools for life sciences research, including proteins, antibodies, and reagents, empowering researchers to explore and innovate in fields ranging from cancer biology to neuroscience. These offerings are developed with meticulous care and a deep understanding of the scientific process, which positions Bio-Techne as a trusted ally to laboratories and research institutions worldwide. The financial heartbeat of Bio-Techne lies in its diverse portfolio, which extends into clinical diagnostics and genomics, segments that are critical in an era of personalized medicine and rapid technological advancement in healthcare. The company's revenue streams are robust, driven by a strategic blend of direct sales and collaborations with major pharmaceutical and biotech companies. Furthermore, Bio-Techne smartly leverages its acquisitions to fortify its market position, enhancing its capabilities and expanding its product lines. This agility and foresight not only enable Bio-Techne to sustain its growth trajectory but also to continually meet the ever-evolving demands of a fast-paced, innovation-driven industry.
See Also
Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.
Based on Bio-Techne Corp's most recent financial statements, the company has Gross Margin of 66.4%.
You don't have any saved screeners yet